cached image

Rudolf Fleischmann

1941-1944 Reichsuniversität Straßburg 
 1947-1953 Universität Hamburg, Hamburg, Hamburg, Germany 
 1953-1969 Friedrich-Alexander-Universität Erlangen, Erlangen, Bayern, Germany 
Nuclear Physics
"Rudolf Fleischmann"

(1903 - 2002)

Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

van der Heijde D, Kartman CE, Xie L, et al. (2021) Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND. The Journal of Rheumatology
Takeuchi T, Fleischmann R, Iikuni N, et al. (2021) Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis Research & Therapy. 23: 220
de Vlam K, Ogdie A, Bushmakin AG, et al. (2021) Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. Rmd Open. 7
Pope JE, Nash P, Fleischmann R. (2021) Current treatment strategies in rheumatoid arthritis after methotrexate are not enough to maintain sustained remission: There is no holy grail! Arthritis & Rheumatology (Hoboken, N.J.)
Fleischmann R, Liu J, Zhu J, et al. (2021) Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. Arthritis Care & Research
Strand V, Tundia N, Bergman M, et al. (2021) Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford, England)
Kerschbaumer A, Smolen JS, Nash P, et al. (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. Rmd Open. 6
Nash P, Kerschbaumer A, Dörner T, et al. (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases
Genovese MC, Burmester GR, Hagino O, et al. (2020) Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research & Therapy. 22: 206
Winthrop KL, Harigai M, Genovese MC, et al. (2020) Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases
See more...